Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $138.39M | $157.75M | $205.75M | $12.36M | $9.54M | $20.79M | $15.75M | $13.00M |
| Cost of Revenue | N/A | N/A | N/A | N/A | $55.95M | N/A | $16.98M | $410.00K |
| Gross Profit | $138.39M | $157.75M | $205.75M | $12.36M | $-46.41M | $20.79M | $-1.23M | $12.59M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | -486.50% | 100.00% | -7.80% | 96.85% |
| Operating Expenses | $234.06M | $235.95M | $193.58M | $215.21M | $25.12M | $46.30M | $20.58M | $23.08M |
| Operating Income | $-95.67M | $-78.20M | $12.18M | $-202.85M | $-71.52M | $-25.51M | $-21.81M | $-10.49M |
| Operating Margin | -69.13% | -49.58% | 5.92% | -1641.33% | -749.81% | -122.72% | -138.46% | -80.72% |
| Net Income | $-80.94M | $-29.73M | $9.35M | $-203.67M | $-72.15M | $-25.99M | $-21.79M | $-10.90M |
| Net Margin | -58.49% | -18.84% | 4.54% | -1647.98% | -756.35% | -125.02% | -138.29% | -83.87% |
| EPS (Basic) | $-3.00 | $-1.12 | $0.35 | $-7.74 | $-3.55 | $-2.13 | $-2.16 | $-3.53 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |